There is now compelling evidence to further evaluate lower doses of abiraterone acetate in men with metastatic prostate cancer: It should be safer, may be as effective and less expensive

Pedro Isaacsson Velho, Mario Eisenberger

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)3059-3060
Number of pages2
JournalJournal of Clinical Oncology
Volume36
Issue number30
DOIs
StatePublished - Oct 20 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this